BLU - Bellus Health jumps 33% on positive BLU-5937 data in mid-stage chronic cough study

Bellus Health (NASDAQ:BLU) soars 33% premarket after announcing that the 50 mg and 200 mg BID doses of BLU-5937 in its Phase 2b SOOTHE trial for the treatment of refractory chronic cough (RCC) achieved statistical significance on the primary endpoint with 34% placebo-adjusted reduction in 24-hour cough frequency observed (p ? 0.005) at day 28. BLU-5937 was generally well-tolerated, with low rates of taste-related adverse events reported (?6.5%) at all doses. The 12.5 mg BID dose demonstrated a statistical trend with 21% reduction in 24-hour cough frequency (p=0.098) with a dose response observed between the 12.5 mg and 50 mg BID doses. BLU-5937 was well-tolerated; safety and tolerability data consistent with previous trials. The Company intends to request an End of Phase 2 meeting with the FDA that is expected to take place in Q2 2022 to discuss Phase 3 program, expected to start in H2 2022.

For further details see:

Bellus Health jumps 33% on positive BLU-5937 data in mid-stage chronic cough study